Swissmedic said the United States pharmaceutical company Pfizer submitted an application for the authorisation of a vaccine which is based on the mRNA technology last week.
The agency added it is fast-tracking all applications connected with the Covid-19 pandemic, assigning extra staff to this task so that content checks and, in particular, user safety are not compromised.
The criteria for reviewing safety, efficacy and quality remain unchanged, according to Claus Bolte, head of Swissmedic’s authorisation division.
“The data packages for the vaccine candidates will be reviewed just as comprehensively, but faster. As a result, we can shorten the waiting times between the development stages during the review,” Bolte said in a statementExternal link published on Monday.
Two weeks ago, the Swiss authorities started assessing an application for a vaccine developed by the British-Swedish company AstraZeneca and Oxford University.
Switzerland has also signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of its Covid-19 vaccine.
Popular Stories
More
Foreign affairs
European nations snub Swiss-made weapons over Ukraine restrictions
Switzerland will deliver rubble removal equipment to Ukraine
This content was published on
Thirty rubble removal machines and thirty fire-fighting pumps: this is the equipment that Switzerland will be delivering to the Ukraine in the next few days. The total value of these goods is 5.6 million Swiss francs.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid cure further away than hoped, says Novartis chief
This content was published on
Swiss pharmaceutical firm Novartis has rowed back on earlier predictions that a drug to combat coronavirus could be on the horizon.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.